Peptide clinical trials & outcomes
Where every peptide in the encyclopedia actually stands in clinical development — approved, in trials, or discontinued and withdrawn — with its highest reached trial phase, the human studies and RCTs counted in PubMed, and its evidence grade. This is the status-first companion to What Works (which ranks by how strong the evidence is): here the question is how far each peptide got, and whether it stalled or failed. A status is not a verdict on any individual use, and nothing here is medical advice. Grey Peptides sells nothing and links to no vendor.
124
FDA approved
106
In trials
74
Approved abroad
60
Discontinued
1
Withdrawn
263
Research only
Discontinued & withdrawn (61)
The honest part vendors leave out: peptides whose development was stopped, whose product was withdrawn, or whose pivotal trial failed. A discontinued or withdrawn status is a strong signal — it usually means the evidence, safety or commercial case did not hold up. Each links to its full entry, where the reason is recorded.
Abarelix · WithdrawnACE-031 · DiscontinuedAclerastide · DiscontinuedAlbiglutide · DiscontinuedAprotinin · DiscontinuedAvorelin · DiscontinuedAzetirelin · DiscontinuedCapreomycin · DiscontinuedCeruletide · DiscontinuedColulintide · DiscontinuedCotadutide · DiscontinuedDanuglipron · DiscontinuedDasiglucagon · DiscontinuedDavalintide · DiscontinuedDemoxytocin · DiscontinuedDepreotide · DiscontinuedDesirudin · DiscontinuedDetirelix · DiscontinuedEbiratide · DiscontinuedElsiglutide · DiscontinuedEnfuvirtide · DiscontinuedGonadorelin · DiscontinuedInsulin detemir · DiscontinuedInsulin peglispro · DiscontinuedIseganan · DiscontinuedLepirudin · DiscontinuedLivoletide · DiscontinuedLixivaptan · DiscontinuedLucinactant · DiscontinuedLutropin alfa · DiscontinuedLypressin · DiscontinuedMecasermin rinfabate · DiscontinuedModimelanotide · DiscontinuedMontirelin · DiscontinuedNemifitide · DiscontinuedNesiritide · DiscontinuedOmiganan · DiscontinuedParathyroid hormone (1-84) · DiscontinuedPegbelfermin · DiscontinuedPeginesatide · DiscontinuedPentagastrin · DiscontinuedPexiganan · DiscontinuedPosatirelin · DiscontinuedPramlintide · DiscontinuedProtirelin · DiscontinuedRamoplanin · DiscontinuedRotigaptide · DiscontinuedSeglitide · DiscontinuedSelepressin · DiscontinuedSerelaxin · DiscontinuedSermorelin · DiscontinuedSomatrem · DiscontinuedSurotomycin · DiscontinuedTabimorelin · DiscontinuedTaspoglutide · DiscontinuedTechnetium Tc 99m Apcitide · DiscontinuedTechnetium Tc 99m Etarfolatide · DiscontinuedThymoctonan · DiscontinuedTifuvirtide · DiscontinuedUlaritide · DiscontinuedZoptarelin Doxorubicin · Discontinued
662 peptides · sorted by development status then trial phase (click a column to re-sort)
| Peptide | Status | Max trial phase | Registered trials | Human studies | RCTs | Grade |
|---|---|---|---|---|---|---|
| Abaloparatide | FDA approved | Phase 4 | 22 | 277 | 32 | High |
| Alprostadil | FDA approved | Phase 4 | 136 | 9,253 | 797 | High |
| Angiotensin II | FDA approved | Phase 4 | 250 | 41,080 | 3,675 | High |
| Anidulafungin | FDA approved | Phase 4 | 35 | 915 | 13 | High |
| Bacitracin | FDA approved | Phase 4 | 36 | 1,884 | 139 | High |
| Bivalirudin | FDA approved | Phase 4 | 72 | 1,765 | 288 | High |
| Bleomycin | FDA approved | Phase 4 | 189 | 11,840 | 593 | High |
| Botulinum Toxin | FDA approved | Phase 4 | 1,048 | 22,038 | 1,690 | High |
| Calcitonin | FDA approved | Phase 4 | 63 | 24,870 | 1,028 | High |
| Carfilzomib | FDA approved | Phase 4 | 305 | 1,392 | 72 | High |
| Caspofungin | FDA approved | Phase 4 | 63 | 2,535 | 55 | High |
| Cetrorelix | FDA approved | Phase 4 | 102 | 553 | 112 | High |
| Colistin | FDA approved | Phase 4 | 91 | 7,551 | 193 | High |
| Copper Cu 64 dotatate | FDA approved | Phase 4 | 8 | 30 | 0 | High |
| Corticorelin | FDA approved | Phase 4 | 26 | 8,178 | 298 | High |
| Corticotropin | FDA approved | Phase 4 | 156 | 35,809 | 1,271 | High |
| Cyclosporine | FDA approved | Phase 4 | 1,184 | 34,891 | 2,298 | High |
| Dactinomycin | FDA approved | Phase 4 | 69 | 6,715 | 144 | High |
| Dalbavancin | FDA approved | Phase 4 | 28 | 566 | 15 | High |
| Daptomycin | FDA approved | Phase 4 | 87 | 2,847 | 49 | High |
| Degarelix | FDA approved | Phase 4 | 149 | 304 | 52 | High |
| Desmopressin | FDA approved | Phase 4 | 78 | 5,337 | 319 | High |
| Dulaglutide | FDA approved | Phase 4 | 113 | 874 | 153 | High |
| Elagolix | FDA approved | Phase 4 | 33 | 145 | 26 | High |
| Elamipretide | FDA approved | Phase 4 | 25 | 202 | 19 | High |
| Eptifibatide | FDA approved | Phase 4 | 36 | 1,189 | 189 | High |
| Erythropoietin (EPO) | FDA approved | Phase 4 | 825 | 26,425 | 1,746 | High |
| Etelcalcetide | FDA approved | Phase 4 | 21 | 114 | 17 | High |
| Exenatide | FDA approved | Phase 4 | 317 | 2,991 | 398 | High |
| Follitropin alfa | FDA approved | Phase 4 | 199 | 1,321 | 83 | High |
| Follitropin beta | FDA approved | Phase 4 | 185 | 180 | 59 | High |
| Gallium Ga 68 dotatate | FDA approved | Phase 4 | 79 | 482 | 2 | High |
| Ganirelix | FDA approved | Phase 4 | 69 | 282 | 77 | High |
| Glatiramer Acetate | FDA approved | Phase 4 | 81 | 3,181 | 129 | High |
| Glucagon | FDA approved | Phase 4 | 1,072 | 37,659 | 3,587 | High |
| Goserelin | FDA approved | Phase 4 | 378 | 1,887 | 437 | High |
| HCG | FDA approved | Phase 4 | 508 | 35,572 | 1,422 | High |
| Hyaluronic Acid | FDA approved | Phase 4 | 652 | 34,639 | 1,932 | High |
| Icatibant | FDA approved | Phase 4 | 26 | 742 | 34 | High |
| IGF-1 | FDA approved | Phase 4 | 188 | 37,304 | 2,408 | High |
| Indium In 111 pentetreotide | FDA approved | Phase 4 | 10 | 693 | 3 | High |
| Insulin aspart | FDA approved | Phase 4 | 476 | 1,385 | 469 | High |
| Insulin degludec | FDA approved | Phase 4 | 204 | 784 | 224 | High |
| Insulin degludec / liraglutide (IDegLira) | FDA approved | Phase 4 | 27 | 4,323 | 758 | High |
| Insulin glargine | FDA approved | Phase 4 | 628 | 3,173 | 914 | High |
| Insulin glargine / lixisenatide (iGlarLixi) | FDA approved | Phase 4 | 16 | 3,511 | 959 | High |
| Insulin glulisine | FDA approved | Phase 4 | 108 | 315 | 85 | High |
| Insulin icodec | FDA approved | Phase 4 | 36 | 113 | 33 | High |
| Insulin lispro | FDA approved | Phase 4 | 317 | 1,396 | 422 | High |
| Lanreotide | FDA approved | Phase 4 | 92 | 1,202 | 92 | High |
| Leuprolide | FDA approved | Phase 4 | 448 | 3,328 | 563 | High |
| Linaclotide | FDA approved | Phase 4 | 46 | 419 | 47 | High |
| Liraglutide | FDA approved | Phase 4 | 399 | 3,480 | 566 | High |
| Lixisenatide | FDA approved | Phase 4 | 67 | 522 | 95 | High |
| Lutetium-177 DOTATATE | FDA approved | Phase 4 | 100 | 2,857 | 56 | High |
| Menotropin | FDA approved | Phase 4 | 107 | 54,103 | 3,697 | High |
| Metreleptin | FDA approved | Phase 4 | 35 | 238 | 29 | High |
| Micafungin | FDA approved | Phase 4 | 60 | 1,499 | 43 | High |
| Motixafortide | FDA approved | Phase 4 | 11 | 48 | 5 | High |
| Nafarelin | FDA approved | Phase 4 | 9 | 318 | 67 | High |
| NPH insulin (isophane) | FDA approved | Phase 4 | 117 | 1,738 | 451 | High |
| Octreotide | FDA approved | Phase 4 | 285 | 10,156 | 541 | High |
| Orforglipron | FDA approved | Phase 4 | 53 | 91 | 19 | Medium |
| Oritavancin | FDA approved | Phase 4 | 18 | 336 | 9 | High |
| Oxytocin | FDA approved | Phase 4 | 510 | 17,006 | 2,151 | High |
| Pasireotide | FDA approved | Phase 4 | 83 | 679 | 55 | High |
| Pegcetacoplan | FDA approved | Phase 4 | 33 | 242 | 34 | High |
| Pegvisomant | FDA approved | Phase 4 | 20 | 624 | 39 | High |
| Piflufolastat F 18 | FDA approved | Phase 4 | 68 | 322 | 4 | High |
| Polymyxin B | FDA approved | Phase 4 | 54 | 3,679 | 167 | High |
| Regular human insulin | FDA approved | Phase 4 | 226 | 322,825 | 23,135 | High |
| Relugolix | FDA approved | Phase 4 | 74 | 191 | 32 | High |
| Rezafungin | FDA approved | Phase 4 | 9 | 216 | 14 | High |
| Romiplostim | FDA approved | Phase 4 | 109 | 792 | 39 | High |
| Secretin | FDA approved | Phase 4 | 37 | 4,807 | 104 | High |
| Semaglutide | FDA approved | Phase 4 | 594 | 3,327 | 313 | High |
| Setmelanotide | FDA approved | Phase 4 | 28 | 158 | 6 | High |
| Somatropin (HGH) | FDA approved | Phase 4 | 533 | 7,503 | 590 | High |
| Sotatercept | FDA approved | Phase 4 | 42 | 189 | 13 | High |
| Teduglutide | FDA approved | Phase 4 | 42 | 279 | 23 | High |
| Telavancin | FDA approved | Phase 4 | 15 | 328 | 18 | High |
| Teriparatide | FDA approved | Phase 4 | 146 | 1,424 | 108 | High |
| Terlipressin | FDA approved | Phase 4 | 76 | 1,092 | 147 | High |
| Tesamorelin | FDA approved | Phase 4 | 16 | 107 | 26 | High |
| Tetracosactide | FDA approved | Phase 4 | 24 | 2,086 | 162 | High |
| Thyrotropin alfa | FDA approved | Phase 4 | 81 | 800 | 48 | High |
| Tirzepatide | FDA approved | Phase 4 | 235 | 1,475 | 136 | High |
| Triptorelin | FDA approved | Phase 4 | 233 | 1,810 | 343 | High |
| Urofollitropin | FDA approved | Phase 4 | 22 | 239 | 59 | High |
| Vancomycin | FDA approved | Phase 4 | 476 | 28,069 | 757 | High |
| Vasopressin | FDA approved | Phase 4 | 274 | 23,749 | 1,349 | High |
| Vipivotide Tetraxetan | FDA approved | Phase 4 | 43 | 1,001 | 33 | High |
| Voclosporin | FDA approved | Phase 4 | 25 | 157 | 16 | High |
| Ziconotide | FDA approved | Phase 4 | 8 | 276 | 4 | High |
| Afamelanotide | FDA approved | Phase 3 | 23 | 437 | 8 | High |
| Apitegromab | FDA approved | Phase 3 | 6 | 12 | 4 | High |
| Bulevirtide | FDA approved | Phase 3 | 10 | 250 | 11 | High |
| Difelikefalin | FDA approved | Phase 3 | 24 | 78 | 13 | High |
| Ecallantide | FDA approved | Phase 3 | 13 | 158 | 11 | High |
| Edotreotide | FDA approved | Phase 3 | 59 | 736 | 4 | High |
| Enlicitide | FDA approved | Phase 3 | 34 | 34 | 5 | High |
| Garetosmab | FDA approved | Phase 3 | 5 | 15 | 6 | Medium |
| Gozetotide | FDA approved | Phase 3 | 30 | 1,665 | 33 | High |
| Gramicidin | FDA approved | Phase 3 | 8 | 681 | 32 | High |
| Histrelin | FDA approved | Phase 3 | 10 | 135 | 2 | High |
| Icotrokinra | FDA approved | Phase 3 | 5 | 21 | 9 | High |
| Insulin efsitora alfa | FDA approved | Phase 3 | 5 | 94 | 29 | High |
| Lonapegsomatropin | FDA approved | Phase 3 | 6 | 35 | 6 | High |
| Macimorelin | FDA approved | Phase 3 | 5 | 32 | 7 | High |
| Mecasermin | FDA approved | Phase 3 | 33 | 26,676 | 1,849 | High |
| Navepegritide | FDA approved | Phase 3 | 6 | 9 | 4 | High |
| Palopegteriparatide | FDA approved | Phase 3 | 3 | 34 | 10 | High |
| Plecanatide | FDA approved | Phase 3 | 15 | 97 | 11 | High |
| PT-141 | FDA approved | Phase 3 | 3 | 92 | 14 | High |
| Romidepsin | FDA approved | Phase 3 | 123 | 784 | 7 | High |
| Rusfertide | FDA approved | Phase 3 | 6 | 17 | 5 | High |
| Somapacitan | FDA approved | Phase 3 | 17 | 65 | 23 | High |
| Somatrogon | FDA approved | Phase 3 | 5 | 54 | 12 | High |
| Trofinetide | FDA approved | Phase 3 | 13 | 54 | 9 | High |
| Vosoritide | FDA approved | Phase 3 | 19 | 89 | 7 | High |
| Zilucoplan | FDA approved | Phase 3 | 21 | 57 | 6 | High |
| Flotufolastat F 18 | FDA approved | Phase 2 | 13 | 10 | 0 | High |
| SS-31 (Elamipretide) | FDA approved | Phase 2 | 2 | 108 | 16 | High |
| Technetium Tc 99m mertiatide | FDA approved | — | — | 967 | 4 | High |
| Albuvirtide | Approved abroad | Phase 4 | 6 | 29 | 5 | High |
| ANP | Approved abroad | Phase 4 | 22 | 16,152 | 1,226 | High |
| Atosiban | Approved abroad | Phase 4 | 16 | 383 | 55 | High |
| Beinaglutide | Approved abroad | Phase 4 | 1 | 331 | 65 | Medium |
| Buserelin | Approved abroad | Phase 4 | 38 | 1,781 | 271 | High |
| Carbetocin | Approved abroad | Phase 4 | 56 | 275 | 67 | High |
| Carperitide | Approved abroad | Phase 4 | 3 | 539 | 33 | Medium |
| Cerebrolysin | Approved abroad | Phase 4 | 36 | 348 | 62 | High |
| Corifollitropin alfa | Approved abroad | Phase 4 | 45 | 122 | 33 | High |
| Efsubaglutide alfa | Approved abroad | Phase 4 | 9 | 14 | 10 | High |
| Felypressin | Approved abroad | Phase 4 | 2 | 171 | 27 | Medium |
| Follitropin delta | Approved abroad | Phase 4 | 25 | 67 | 21 | High |
| Mazdutide | Approved abroad | Phase 4 | 40 | 40 | 11 | High |
| Pegmolesatide | Approved abroad | Phase 4 | 2 | 6 | 0 | Medium |
| Polaprezinc | Approved abroad | Phase 4 | 6 | 141 | 31 | High |
| Polyethylene glycol loxenatide | Approved abroad | Phase 4 | 13 | 25 | 9 | High |
| Recombinant Human Endostatin | Approved abroad | Phase 4 | 116 | 390 | 43 | Medium |
| Somatostatin | Approved abroad | Phase 4 | 283 | 24,896 | 1,176 | High |
| Sovateltide | Approved abroad | Phase 4 | 11 | 52 | 2 | Medium |
| Taltirelin | Approved abroad | Phase 4 | 1 | 22 | 0 | Medium |
| Teicoplanin | Approved abroad | Phase 4 | 18 | 2,847 | 122 | High |
| Tyrothricin | Approved abroad | Phase 4 | 5 | 153 | 7 | Medium |
| Anamorelin | Approved abroad | Phase 3 | 12 | 135 | 12 | High |
| Brimapitide | Approved abroad | Phase 3 | 1 | 27 | 4 | Medium |
| Ecnoglutide | Approved abroad | Phase 3 | 16 | 12 | 5 | High |
| Forigerimod | Approved abroad | Phase 3 | 2 | 22 | 2 | High |
| Melphalan Flufenamide | Approved abroad | Phase 3 | 11 | 56 | 3 | High |
| Plitidepsin | Approved abroad | Phase 3 | 18 | 121 | 6 | Medium |
| PSMA-1007 | Approved abroad | Phase 3 | 19 | 317 | 6 | Medium |
| Tertomotide | Approved abroad | Phase 3 | 9 | 58 | 5 | High |
| Thrombomodulin Alfa | Approved abroad | Phase 3 | 3 | 59 | 9 | High |
| Thymopentin | Approved abroad | Phase 3 | 5 | 459 | 54 | Medium |
| Thymosin α1 | Approved abroad | Phase 3 | 7 | 556 | 64 | High |
| Thymostimulin | Approved abroad | Phase 3 | 7 | 151 | 37 | Medium |
| Trafermin | Approved abroad | Phase 3 | 7 | 110 | 12 | High |
| DAPTA | Approved abroad | Phase 2 | 1 | 30 | 2 | Medium |
| Dolcanatide | Approved abroad | Phase 2 | 3 | 4 | 0 | Low |
| Edratide | Approved abroad | Phase 2 | 1 | 41 | 0 | Medium |
| HYNIC-TOC | Approved abroad | Phase 2 | 1 | 132 | 0 | Medium |
| Lancovutide | Approved abroad | Phase 2 | 1 | 60 | 3 | Medium |
| Mifamurtide | Approved abroad | Phase 2 | 4 | 92 | 6 | High |
| Ozarelix | Approved abroad | Phase 2 | 3 | 3 | 0 | Low |
| Rusalatide | Approved abroad | Phase 2 | 1 | 23 | 1 | Low |
| Testagen | Approved abroad | Phase 2 | 1 | 1 | 0 | Low |
| Dalazatide | Approved abroad | Phase 1 | 2 | 13 | 1 | Medium |
| Veldoreotide | Approved abroad | Phase 1 | 1 | 13 | 0 | Low |
| Amilomotide | Approved abroad | — | — | 10 | 2 | Medium |
| Cerluten | Approved abroad | — | — | 0 | 0 | Low |
| Cortexin | Approved abroad | — | — | 3,669 | 46 | Low |
| Disomotide | Approved abroad | — | — | 19 | 1 | Medium |
| Eftansomatropin alfa | Approved abroad | — | — | 1 | 1 | Medium |
| Elcatonin | Approved abroad | — | — | 82 | 15 | Medium |
| Elpamotide | Approved abroad | — | — | 8 | 1 | Medium |
| Endoluten | Approved abroad | — | — | 0 | 0 | Low |
| GHRP-2 | Approved abroad | — | — | 161 | 43 | Medium |
| Leconotide | Approved abroad | — | — | 1 | 0 | Low |
| Lusupultide | Approved abroad | — | — | 23 | 5 | Medium |
| Murabutide | Approved abroad | — | — | 46 | 3 | Low |
| Nendratareotide Uzatansine | Approved abroad | — | — | 5 | 0 | Low |
| Noopept | Approved abroad | — | — | 31 | 0 | Medium |
| Ornipressin | Approved abroad | — | — | 157 | 12 | Medium |
| Prostamax | Approved abroad | — | — | 8 | 0 | Low |
| Prostatilen | Approved abroad | — | — | 18 | 2 | Low |
| Retinalamin | Approved abroad | — | — | 16 | 3 | Low |
| Romurtide | Approved abroad | — | — | 34 | 6 | Medium |
| Selank | Approved abroad | — | — | 45 | 3 | Medium |
| Semax | Approved abroad | — | — | 54 | 1 | Medium |
| Thymalin | Approved abroad | — | — | 200 | 2 | Low |
| Thymodepressin | Approved abroad | — | — | 6 | 0 | Low |
| Thymogen | Approved abroad | — | — | 94 | 7 | Low |
| Thymomodulin | Approved abroad | — | — | 37 | 7 | Medium |
| Tiplimotide | Approved abroad | — | — | 2 | 0 | Medium |
| Ventfort | Approved abroad | — | — | 0 | 0 | Low |
| Visoluten | Approved abroad | — | — | 0 | 0 | Low |
| Alfatide II | In trials | Phase 4 | 6 | 15 | 1 | Medium |
| Avexitide | In trials | Phase 4 | 36 | 223 | 35 | Medium |
| DOTANOC | In trials | Phase 4 | 7 | 362 | 2 | Medium |
| GDF15 | In trials | Phase 4 | 22 | 4,421 | 183 | High |
| VIP | In trials | Phase 4 | 50 | 5,488 | 97 | Medium |
| AlF-NOTA-octreotide | In trials | Phase 3 | 6 | 25 | 0 | Medium |
| AZD6234 | In trials | Phase 3 | 15 | 2 | 0 | Low |
| Balixafortide | In trials | Phase 3 | 10 | 13 | 0 | Medium |
| Bimagrumab | In trials | Phase 3 | 19 | 88 | 15 | Medium |
| Bofanglutide | In trials | Phase 3 | 2 | 7 | 6 | Medium |
| Cagrilintide | In trials | Phase 3 | 44 | 403 | 75 | Medium |
| Canvuparatide | In trials | Phase 3 | 2 | 3 | 2 | Medium |
| Cilengitide | In trials | Phase 3 | 33 | 287 | 17 | Medium |
| CP04 | In trials | Phase 3 | 2 | 8 | 0 | Medium |
| Davunetide | In trials | Phase 3 | 6 | 119 | 10 | Medium |
| Dirucotide | In trials | Phase 3 | 7 | 9 | 2 | Medium |
| Dusquetide | In trials | Phase 3 | 2 | 4 | 2 | Medium |
| ECC5004 | In trials | Phase 3 | 7 | 2 | 2 | Medium |
| Efpeglenatide | In trials | Phase 3 | 5 | 38 | 12 | High |
| Efruxifermin | In trials | Phase 3 | 6 | 27 | 6 | Medium |
| Eloralintide | In trials | Phase 3 | 20 | 7 | 3 | Medium |
| Eneboparatide | In trials | Phase 3 | 3 | 5 | 0 | Medium |
| Enicepatide | In trials | Phase 3 | 8 | 2 | 1 | Medium |
| Fexapotide | In trials | Phase 3 | 7 | 26 | 2 | Medium |
| Galinpepimut-S | In trials | Phase 3 | 8 | 4 | 1 | Medium |
| Glepaglutide | In trials | Phase 3 | 9 | 26 | 8 | Medium |
| HRS-9531 | In trials | Phase 3 | 33 | 0 | 0 | Medium |
| Insulin tregopil | In trials | Phase 3 | 4 | 4,298 | 212 | Low |
| Kisspeptin-10 | In trials | Phase 3 | 5 | 748 | 17 | Medium |
| Kisspeptin-54 | In trials | Phase 3 | 20 | 1,231 | 29 | Medium |
| Larazotide | In trials | Phase 3 | 28 | 72 | 6 | Medium |
| LSALT peptide | In trials | Phase 3 | 4 | 4 | 1 | Low |
| Maridebart cafraglutide | In trials | Phase 3 | 28 | 15 | 2 | Medium |
| Murepavadin | In trials | Phase 3 | 6 | 24 | 1 | Medium |
| Nelipepimut-S | In trials | Phase 3 | 4 | 11 | 5 | High |
| Nerinetide | In trials | Phase 3 | 3 | 1,354 | 45 | Medium |
| Olatorepatide | In trials | Phase 3 | 4 | 0 | 0 | Medium |
| Pegozafermin | In trials | Phase 3 | 8 | 25 | 6 | Medium |
| Pemvidutide | In trials | Phase 3 | 8 | 9 | 2 | Medium |
| Pentixafor | In trials | Phase 3 | 22 | 259 | 1 | Medium |
| Petrelintide | In trials | Phase 3 | 9 | 32 | 7 | Medium |
| Relamorelin | In trials | Phase 3 | 13 | 40 | 10 | Medium |
| Retatrutide | In trials | Phase 3 | 32 | 136 | 10 | Medium |
| RM2 | In trials | Phase 3 | 20 | 155 | 6 | Medium |
| SAR-bisPSMA | In trials | Phase 3 | 10 | 1 | 0 | Medium |
| Survodutide | In trials | Phase 3 | 29 | 58 | 10 | High |
| Taldefgrobep alfa | In trials | Phase 3 | 4 | 4 | 0 | Medium |
| Tecemotide | In trials | Phase 3 | 14 | 41 | 9 | Medium |
| Tozuleristide | In trials | Phase 3 | 10 | 11 | 0 | Medium |
| UBT251 | In trials | Phase 3 | 14 | 0 | 0 | Medium |
| Ulimorelin | In trials | Phase 3 | 11 | 23 | 9 | Medium |
| Vapreotide | In trials | Phase 3 | 2 | 137 | 4 | High |
| VK2735 | In trials | Phase 3 | 8 | 1 | 1 | Medium |
| Zadavotide Guraxetan | In trials | Phase 3 | 1 | 172 | 3 | Medium |
| Zelpultide alfa | In trials | Phase 3 | 3 | 0 | 0 | Low |
| ARA-290 | In trials | Phase 2 | 5 | 41 | 4 | Medium |
| Cenderitide | In trials | Phase 2 | 13 | 29 | 2 | Low |
| Certepetide | In trials | Phase 2 | 10 | 301 | 0 | Medium |
| Danegaptide | In trials | Phase 2 | 1 | 11 | 1 | Medium |
| Dapiglutide | In trials | Phase 2 | 2 | 1 | 0 | Medium |
| DOTA-EB-TATE | In trials | Phase 2 | 5 | 9 | 0 | Medium |
| DOTA-LM3 | In trials | Phase 2 | 6 | 8 | 3 | Medium |
| DOTA-MGS5 | In trials | Phase 2 | 2 | 8 | 0 | Medium |
| DOTAMTATE | In trials | Phase 2 | 1 | 4 | 0 | Medium |
| Efinopegdutide | In trials | Phase 2 | 7 | 9 | 3 | Medium |
| Efocipegtrutide | In trials | Phase 2 | 3 | 4 | 0 | Low |
| FAP-2286 | In trials | Phase 2 | 8 | 61 | 0 | Medium |
| Fluciclatide | In trials | Phase 2 | 12 | 12 | 0 | Medium |
| FPPRGD2 | In trials | Phase 2 | 4 | 18 | 0 | Medium |
| HM15136 | In trials | Phase 2 | 3 | 3 | 2 | Low |
| HM15275 | In trials | Phase 2 | 3 | 0 | 0 | Low |
| Maraciclatide | In trials | Phase 2 | 2 | 14 | 3 | Medium |
| Nangibotide | In trials | Phase 2 | 4 | 110 | 6 | Medium |
| NeoB | In trials | Phase 2 | 8 | 22 | 0 | Medium |
| NODAGA-exendin-4 | In trials | Phase 2 | 7 | 9 | 0 | Medium |
| PB-718 | In trials | Phase 2 | 3 | 0 | 0 | Low |
| Pentixather | In trials | Phase 2 | 6 | 35 | 0 | Medium |
| PSMA I&S | In trials | Phase 2 | 4 | 3 | 0 | Medium |
| Ruxotemitide | In trials | Phase 2 | 1 | 39 | 0 | Low |
| SARTATE | In trials | Phase 2 | 6 | 5 | 0 | Medium |
| Satoreotide Tetraxetan | In trials | Phase 2 | 4 | 13 | 0 | Medium |
| Satoreotide Trizoxetan | In trials | Phase 2 | 6 | 11 | 1 | Medium |
| Solnatide | In trials | Phase 2 | 2 | 21 | 6 | Medium |
| Sonefpeglutide | In trials | Phase 2 | 3 | 1 | 0 | Low |
| Tesofensine | In trials | Phase 2 | 14 | 48 | 11 | Medium |
| Teverelix | In trials | Phase 2 | 4 | 12 | 2 | Medium |
| Thymosin β4 | In trials | Phase 2 | 5 | 595 | 8 | Medium |
| Trevogrumab | In trials | Phase 2 | 1 | 4 | 0 | Low |
| VMT-α-NET | In trials | Phase 2 | 4 | 3 | 0 | Medium |
| Zelenectide Pevedotin | In trials | Phase 2 | 4 | 8 | 0 | Medium |
| Amycretin | In trials | Phase 1 | 1 | 15 | 4 | Medium |
| GMA106 | In trials | Phase 1 | 1 | 0 | 0 | Low |
| KN056 | In trials | Phase 1 | 1 | 1 | 1 | Low |
| 3PRGD2 | In trials | — | — | 40 | 0 | Medium |
| Dazdotuftide | In trials | — | — | 9 | 1 | Medium |
| Efmedaglutide alfa | In trials | — | — | 3 | 2 | Low |
| Galacto-RGD | In trials | — | — | 32 | 0 | Medium |
| Obinepitide | In trials | — | — | 1 | 0 | Low |
| Pegsebrenatide | In trials | — | — | 12 | 1 | Medium |
| Rovatirelin | In trials | — | — | 4 | 1 | Medium |
| SiTATE | In trials | — | — | 27 | 0 | Medium |
| Trivehexin | In trials | — | — | 31 | 0 | Medium |
| Trofolastat | In trials | — | — | 10 | 1 | Medium |
| Ubiquicidin 29-41 | In trials | — | — | 39 | 0 | Medium |
| Utreglutide | In trials | — | — | 1 | 0 | Low |
| αCT1 (Alpha Connexin Carboxyl-Terminus 1) | In trials | — | — | 343 | 16 | Medium |
| Apraglutide | In development | Phase 3 | 11 | 25 | 2 | High |
| CagriSema | In development | Phase 3 | 31 | 40 | 10 | High |
| Follistatin-344 | Preclinical | Phase 1 | 1 | 1,733 | 68 | Low |
| Adipotide | Preclinical | — | — | 8 | 0 | Low |
| B7-33 | Preclinical | — | — | 10 | 0 | Low |
| Follistatin-315 | Preclinical | — | — | 15 | 0 | Low |
| FOXO4-DRI | Preclinical | — | — | 9 | 0 | Low |
| PEPITEM | Preclinical | — | — | 9 | 0 | Low |
| Plectasin | Preclinical | — | — | 20 | 0 | Low |
| PNC-27 | Preclinical | — | — | 18 | 0 | Low |
| Teixobactin | Preclinical | — | — | 32 | 0 | Low |
| Albiglutide | Discontinued | Phase 4 | 35 | 243 | 40 | High |
| Aprotinin | Discontinued | Phase 4 | 18 | 3,445 | 416 | High |
| Capreomycin | Discontinued | Phase 4 | 2 | 482 | 0 | Medium |
| Desirudin | Discontinued | Phase 4 | 5 | 66 | 10 | High |
| Enfuvirtide | Discontinued | Phase 4 | 51 | 969 | 65 | High |
| Gonadorelin | Discontinued | Phase 4 | 964 | 24,018 | 2,458 | Medium |
| Insulin detemir | Discontinued | Phase 4 | 148 | 913 | 170 | High |
| Lepirudin | Discontinued | Phase 4 | 7 | 475 | 11 | High |
| Lutropin alfa | Discontinued | Phase 4 | 65 | 2,526 | 294 | Medium |
| Lypressin | Discontinued | Phase 4 | 58 | 303 | 20 | Low |
| Mecasermin rinfabate | Discontinued | Phase 4 | 158 | 623 | 21 | Medium |
| Montirelin | Discontinued | Phase 4 | 18 | 268 | 20 | Low |
| Nesiritide | Discontinued | Phase 4 | 108 | 21,585 | 1,942 | High |
| Parathyroid hormone (1-84) | Discontinued | Phase 4 | 27 | 725 | 80 | High |
| Peginesatide | Discontinued | Phase 4 | 19 | 52 | 2 | High |
| Pentagastrin | Discontinued | Phase 4 | 5 | 2,164 | 167 | Medium |
| Pramlintide | Discontinued | Phase 4 | 47 | 404 | 67 | High |
| Sermorelin | Discontinued | Phase 4 | 17 | 291 | 38 | Medium |
| Aclerastide | Discontinued | Phase 3 | 4 | 1 | 1 | Low |
| Dasiglucagon | Discontinued | Phase 3 | 23 | 36 | 13 | High |
| Insulin peglispro | Discontinued | Phase 3 | 13 | 49 | 27 | High |
| Iseganan | Discontinued | Phase 3 | 3 | 41 | 6 | High |
| Livoletide | Discontinued | Phase 3 | 2 | 4 | 2 | Low |
| Lixivaptan | Discontinued | Phase 3 | 10 | 93 | 11 | Medium |
| Lucinactant | Discontinued | Phase 3 | 11 | 45 | 6 | High |
| Omiganan | Discontinued | Phase 3 | 14 | 35 | 5 | High |
| Pexiganan | Discontinued | Phase 3 | 4 | 60 | 1 | High |
| Protirelin | Discontinued | Phase 3 | 12 | 9,961 | 267 | High |
| Selepressin | Discontinued | Phase 3 | 2 | 22 | 1 | Medium |
| Serelaxin | Discontinued | Phase 3 | 14 | 170 | 35 | High |
| Surotomycin | Discontinued | Phase 3 | 4 | 36 | 5 | High |
| Taspoglutide | Discontinued | Phase 3 | 13 | 55 | 11 | High |
| Ularitide | Discontinued | Phase 3 | 4 | 204 | 34 | High |
| Zoptarelin Doxorubicin | Discontinued | Phase 3 | 2 | 58 | 0 | Medium |
| ACE-031 | Discontinued | Phase 2 | 4 | 29 | 2 | Medium |
| Cotadutide | Discontinued | Phase 2 | 24 | 51 | 14 | Medium |
| Danuglipron | Discontinued | Phase 2 | 20 | 37 | 5 | Medium |
| Davalintide | Discontinued | Phase 2 | 1 | 8 | 0 | Low |
| Elsiglutide | Discontinued | Phase 2 | 2 | 0 | 0 | Low |
| Pegbelfermin | Discontinued | Phase 2 | 11 | 17 | 5 | Medium |
| Rotigaptide | Discontinued | Phase 2 | 2 | 15 | 2 | Medium |
| Technetium Tc 99m Etarfolatide | Discontinued | Phase 2 | 4 | 17 | 2 | Medium |
| Avorelin | Discontinued | — | — | 1 | 1 | Low |
| Azetirelin | Discontinued | — | — | 3 | 0 | Low |
| Ceruletide | Discontinued | — | — | 1,051 | 50 | Low |
| Colulintide | Discontinued | — | — | 0 | 0 | Low |
| Demoxytocin | Discontinued | — | — | 80 | 5 | Medium |
| Depreotide | Discontinued | — | — | 90 | 1 | Medium |
| Detirelix | Discontinued | — | — | 5 | 1 | Medium |
| Ebiratide | Discontinued | — | — | 4 | 1 | Low |
| Modimelanotide | Discontinued | — | — | 5 | 1 | Medium |
| Nemifitide | Discontinued | — | — | 18 | 6 | Medium |
| Posatirelin | Discontinued | — | — | 8 | 2 | Medium |
| Ramoplanin | Discontinued | — | — | 64 | 1 | Medium |
| Seglitide | Discontinued | — | — | 25 | 0 | Medium |
| Somatrem | Discontinued | — | — | 94 | 11 | Medium |
| Tabimorelin | Discontinued | — | — | 7 | 4 | Low |
| Technetium Tc 99m Apcitide | Discontinued | — | — | 41 | 4 | Medium |
| Thymoctonan | Discontinued | — | — | 18 | 0 | Low |
| Tifuvirtide | Discontinued | — | — | 64 | 1 | Medium |
| Abarelix | Withdrawn | Phase 4 | 4 | 51 | 2 | High |
| Amylin | Research only | Phase 4 | 91 | 3,602 | 213 | Low |
| Angiotensin-(1-7) | Research only | Phase 4 | 76 | 1,426 | 32 | Medium |
| Apelin | Research only | Phase 4 | 12 | 1,675 | 42 | Medium |
| Asprosin | Research only | Phase 4 | 14 | 236 | 16 | Low |
| Beta-Endorphin | Research only | Phase 4 | 113 | 7,648 | 477 | Medium |
| Beta-lipotropin | Research only | Phase 4 | 4 | 552 | 16 | Low |
| Bradykinin | Research only | Phase 4 | 38 | 8,791 | 309 | Medium |
| C-peptide | Research only | Phase 4 | 2,225 | 13,181 | 1,783 | Medium |
| Catestatin | Research only | Phase 4 | 8 | 174 | 1 | Low |
| Cathelicidin | Research only | Phase 4 | 10 | 2,786 | 55 | Low |
| CGRP | Research only | Phase 4 | 91 | 9,803 | 561 | Medium |
| CNP | Research only | Phase 4 | 29 | 996 | 29 | Low |
| Copeptin | Research only | Phase 4 | 121 | 1,380 | 99 | Medium |
| Cortistatin | Research only | Phase 4 | 11 | 194 | 5 | Low |
| Dynorphin | Research only | Phase 4 | 4 | 9,350 | 190 | Low |
| Elabela | Research only | Phase 4 | 45 | 6,423 | 430 | Low |
| Endothelin-1 | Research only | Phase 4 | 24 | 18,754 | 1,181 | Medium |
| Gastrin | Research only | Phase 4 | 55 | 9,845 | 459 | Low |
| GHK-Cu | Research only | Phase 4 | 3 | 67 | 3 | Medium |
| Ghrelin | Research only | Phase 4 | 88 | 11,055 | 1,685 | Medium |
| GIP | Research only | Phase 4 | 110 | 6,652 | 768 | Medium |
| GLP-1 | Research only | Phase 4 | 1,399 | 19,633 | 2,316 | Medium |
| GLP-2 | Research only | Phase 4 | 1,092 | 1,210 | 185 | Medium |
| Glutathione | Research only | Phase 4 | 154 | 61,221 | 1,879 | Low |
| Growth hormone-releasing hormone | Research only | Phase 4 | 68 | 3,412 | 285 | Medium |
| hBD-1 | Research only | Phase 4 | 4 | 787 | 10 | Low |
| Hepcidin | Research only | Phase 4 | 38 | 4,148 | 237 | Medium |
| Irisin | Research only | Phase 4 | 2 | 1,637 | 103 | Low |
| Katacalcin | Research only | Phase 4 | 63 | 68 | 0 | Medium |
| Klotho Peptide | Research only | Phase 4 | 2 | 2,669 | 67 | Medium |
| Kyotorphin | Research only | Phase 4 | 1 | 133 | 3 | Low |
| Melanocyte-stimulating hormone beta | Research only | Phase 4 | 4 | 254 | 0 | Medium |
| MGF | Research only | Phase 4 | 62 | 9,581 | 316 | Low |
| Motilin | Research only | Phase 4 | 14 | 1,150 | 180 | Low |
| NAD+ | Research only | Phase 4 | 173 | 314 | 16 | Medium |
| Neurokinin A | Research only | Phase 4 | 49 | 694 | 27 | Medium |
| Neuropeptide S | Research only | Phase 4 | 20 | 193 | 1 | Low |
| Neuropeptide Y | Research only | Phase 4 | 9 | 6,034 | 149 | Medium |
| Neurotensin | Research only | Phase 4 | 5 | 2,211 | 48 | Medium |
| Nociceptin | Research only | Phase 4 | 8 | 694 | 15 | Low |
| Obestatin | Research only | Phase 4 | 88 | 356 | 13 | Low |
| Orexin-A | Research only | Phase 4 | 51 | 2,184 | 47 | Low |
| Orexin-B | Research only | Phase 4 | 51 | 2,005 | 44 | Low |
| Osteocalcin | Research only | Phase 4 | 12 | 12,534 | 1,211 | Low |
| PACAP | Research only | Phase 4 | 7 | 1,341 | 36 | Medium |
| Palmitoyl Dipeptide-10 | Research only | Phase 4 | 1 | 0 | 0 | Low |
| Palmitoyl Tetrapeptide-7 | Research only | Phase 4 | 1 | 5 | 1 | Low |
| Palmitoyl Tripeptide-5 | Research only | Phase 4 | 1 | 3 | 0 | Low |
| Pancreastatin | Research only | Phase 4 | 8 | 178 | 0 | Medium |
| Pancreatic polypeptide | Research only | Phase 4 | 25 | 2,294 | 181 | Medium |
| Parathyroid hormone-related protein | Research only | Phase 4 | 16 | 2,911 | 10 | Medium |
| Peptide YY | Research only | Phase 4 | 11 | 2,896 | 557 | Medium |
| PHM-27 | Research only | Phase 4 | 11 | 130 | 2 | Low |
| Prolactin-releasing peptide | Research only | Phase 4 | 17 | 107 | 3 | Low |
| Salusin-alpha | Research only | Phase 4 | 1 | 63 | 0 | Low |
| Salusin-beta | Research only | Phase 4 | 1 | 81 | 1 | Low |
| Substance P | Research only | Phase 4 | 68 | 9,219 | 505 | Medium |
| Vasostatin (Chromogranin A) | Research only | Phase 4 | 8 | 32,893 | 4,614 | Low |
| Alpha-MSH | Research only | Phase 3 | 6 | 4,689 | 67 | Low |
| Argireline | Research only | Phase 3 | 5 | 60 | 3 | Medium |
| Bombesin | Research only | Phase 3 | 37 | 1,827 | 14 | Medium |
| Des-acyl Ghrelin (Unacylated Ghrelin) | Research only | Phase 3 | 3 | 324 | 28 | Medium |
| Enkephalin | Research only | Phase 3 | 11 | 4,742 | 89 | Medium |
| Gastrin-releasing peptide | Research only | Phase 3 | 37 | 1,616 | 5 | Medium |
| HNP-1 | Research only | Phase 3 | 2 | 485 | 6 | Low |
| LL-37 | Research only | Phase 3 | 10 | 2,821 | 56 | Low |
| MK-677 | Research only | Phase 3 | 8 | 105 | 19 | Medium |
| Neurokinin B | Research only | Phase 3 | 4 | 476 | 14 | Medium |
| Adrenomedullin | Research only | Phase 2 | 11 | 2,757 | 84 | Medium |
| Adrenomedullin 2 | Research only | Phase 2 | 6 | 170 | 0 | Low |
| BPC-157 | Research only | Phase 2 | 3 | 54 | 0 | Low |
| CART peptide | Research only | Phase 2 | 14 | 66 | 0 | Low |
| CJC-1295 | Research only | Phase 2 | 1 | 25 | 1 | Medium |
| Cyclo(His-Pro) | Research only | Phase 2 | 2 | 56 | 1 | Low |
| GHRP-1 | Research only | Phase 2 | 1 | 24 | 3 | Low |
| Goralatide | Research only | Phase 2 | 2 | 178 | 10 | Low |
| hBD-2 | Research only | Phase 2 | 1 | 1,424 | 29 | Low |
| Ipamorelin | Research only | Phase 2 | 2 | 29 | 2 | Medium |
| Lunasin | Research only | Phase 2 | 1 | 85 | 1 | Low |
| Melanotan II | Research only | Phase 2 | 1 | 104 | 1 | Medium |
| MOTS-c | Research only | Phase 2 | 1 | 152 | 4 | Low |
| Muramyl Dipeptide | Research only | Phase 2 | 3 | 704 | 9 | Low |
| Osteogenic growth peptide | Research only | Phase 2 | 1 | 47 | 0 | Low |
| Oxyntomodulin | Research only | Phase 2 | 5 | 231 | 28 | Medium |
| P21 | Research only | Phase 2 | 6 | 25,382 | 52 | Low |
| PEG-MGF | Research only | Phase 2 | 1 | 5 | 1 | Low |
| Preptin | Research only | Phase 2 | 3 | 48 | 1 | Low |
| TB-500 | Research only | Phase 2 | 2 | 25 | 0 | Low |
| Thiostrepton | Research only | Phase 2 | 2 | 170 | 0 | Low |
| Urocortin | Research only | Phase 2 | 2 | 594 | 6 | Medium |
| Urotensin II | Research only | Phase 2 | 1 | 579 | 10 | Low |
| HD5 | Research only | Phase 1 | 1 | 1,975 | 67 | Low |
| HD6 | Research only | Phase 1 | 1 | 167 | 7 | Low |
| Xenin | Research only | Phase 1 | 6 | 38 | 2 | Medium |
| AHK-Cu | Research only | Early Phase 1 | 1 | 1 | 0 | Low |
| Epithalon | Research only | Early Phase 1 | 1 | 51 | 0 | Low |
| 5-Amino-1MQ | Research only | — | — | 3 | 0 | Low |
| Acetyl Decapeptide-3 | Research only | — | — | 0 | 0 | Low |
| Acetyl Dipeptide-1 Cetyl Ester | Research only | — | — | 4 | 2 | Low |
| Acetyl Dipeptide-3 Aminohexanoate | Research only | — | — | 0 | 0 | Low |
| Acetyl Heptapeptide-4 | Research only | — | — | 0 | 0 | Low |
| Acetyl Hexapeptide-1 | Research only | — | — | 2 | 0 | Low |
| Acetyl Hexapeptide-30 | Research only | — | — | 0 | 0 | Low |
| Acetyl Hexapeptide-37 | Research only | — | — | 0 | 0 | Low |
| Acetyl Hexapeptide-38 | Research only | — | — | 0 | 0 | Low |
| Acetyl Hexapeptide-49 | Research only | — | — | 0 | 0 | Low |
| Acetyl Hexapeptide-51 Amide | Research only | — | — | 0 | 0 | Low |
| Acetyl Octapeptide-3 | Research only | — | — | 1 | 0 | Low |
| Acetyl Pentapeptide-1 | Research only | — | — | 0 | 0 | Low |
| Acetyl SH-Heptapeptide-1 | Research only | — | — | 0 | 0 | Low |
| Acetyl Tetrapeptide-11 | Research only | — | — | 1 | 0 | Low |
| Acetyl Tetrapeptide-15 | Research only | — | — | 0 | 0 | Low |
| Acetyl Tetrapeptide-2 | Research only | — | — | 1 | 1 | Low |
| Acetyl Tetrapeptide-22 | Research only | — | — | 0 | 0 | Low |
| Acetyl Tetrapeptide-3 | Research only | — | — | 0 | 0 | Low |
| Acetyl Tetrapeptide-5 | Research only | — | — | 1 | 0 | Low |
| Acetyl Tetrapeptide-9 | Research only | — | — | 1 | 0 | Low |
| Acetyl Tripeptide-1 | Research only | — | — | 0 | 0 | Low |
| Adamax | Research only | — | — | 14 | 0 | Low |
| Adropin | Research only | — | — | 256 | 13 | Low |
| Agouti-Related Peptide (AgRP) | Research only | — | — | 687 | 15 | Low |
| Alexamorelin | Research only | — | — | 8 | 0 | Low |
| AOD-9604 | Research only | — | — | 19 | 0 | Medium |
| Apamin | Research only | — | — | 480 | 0 | Low |
| Augurin (ECRG4) | Research only | — | — | 89 | 0 | Low |
| Balenine | Research only | — | — | 14 | 0 | Medium |
| Biotinoyl Tripeptide-1 | Research only | — | — | 0 | 0 | Low |
| BRN2 (POU3F2) Research Peptide | Research only | — | — | 0 | 0 | Low |
| Bronchogen | Research only | — | — | 7 | 0 | Low |
| Caprooyl Tetrapeptide-3 | Research only | — | — | 0 | 0 | Low |
| Cardiogen | Research only | — | — | 26 | 0 | Low |
| Cartalax | Research only | — | — | 35 | 0 | Low |
| Cecropin | Research only | — | — | 259 | 3 | Low |
| Chonluten | Research only | — | — | 58 | 0 | Low |
| Chromofungin | Research only | — | — | 15 | 0 | Low |
| CJC-1293 | Research only | — | — | 3 | 0 | Low |
| Cortagen | Research only | — | — | 26 | 0 | Low |
| Corticotropin-like intermediate peptide (CLIP) | Research only | — | — | 40 | 0 | Low |
| Cyclic Glycine-Proline | Research only | — | — | 13 | 0 | Low |
| D-4F | Research only | — | — | 42 | 1 | Low |
| Decapeptide-12 | Research only | — | — | 6 | 1 | Low |
| Deltorphin | Research only | — | — | 74 | 1 | Low |
| Dermcidin | Research only | — | — | 232 | 2 | Medium |
| Dermorphin | Research only | — | — | 61 | 1 | Low |
| Dihexa | Research only | — | — | 9 | 0 | Low |
| Dipeptide-2 | Research only | — | — | 25 | 0 | Low |
| DSIP | Research only | — | — | 141 | 6 | Medium |
| EM66 | Research only | — | — | 18 | 0 | Low |
| Endomorphin-1 | Research only | — | — | 210 | 9 | Low |
| Enterostatin | Research only | — | — | 47 | 2 | Low |
| Epithalamin | Research only | — | — | 30 | 5 | Low |
| FGL Peptide | Research only | — | — | 1 | 0 | Low |
| FK-13 | Research only | — | — | 33 | 0 | Medium |
| Galanin | Research only | — | — | 1,341 | 25 | Medium |
| Galanin-like Peptide (GALP) | Research only | — | — | 481 | 0 | Low |
| GAWK (Chromogranin B 420-493) | Research only | — | — | 11 | 0 | Low |
| GDF11 | Research only | — | — | 322 | 4 | Low |
| GHRP-4 | Research only | — | — | 6 | 0 | Low |
| GHRP-5 | Research only | — | — | 6 | 0 | Low |
| GHRP-6 | Research only | — | — | 323 | 25 | Medium |
| Glicentin | Research only | — | — | 161 | 10 | Low |
| Glypromate | Research only | — | — | 24 | 0 | Low |
| Guanylin | Research only | — | — | 248 | 0 | Low |
| hBD-3 | Research only | — | — | 705 | 5 | Low |
| Hemopressin (Hp) | Research only | — | — | 32 | 1 | Low |
| Hexanoyl Dipeptide-3 Norleucine Acetate | Research only | — | — | 0 | 0 | Low |
| Hexapeptide-10 | Research only | — | — | 32 | 0 | Low |
| Hexapeptide-11 | Research only | — | — | 5 | 0 | Low |
| Hexapeptide-33 | Research only | — | — | 1 | 0 | Low |
| Hexapeptide-9 | Research only | — | — | 1 | 1 | Low |
| Hexarelin | Research only | — | — | 193 | 27 | Medium |
| Histatin | Research only | — | — | 671 | 26 | Medium |
| Humanin | Research only | — | — | 335 | 6 | Low |
| IGF-1 DES(1-3) | Research only | — | — | 14 | 0 | Low |
| IGF-1 LR3 | Research only | — | — | 41 | 1 | Low |
| Indolicidin | Research only | — | — | 96 | 2 | Low |
| INSL3 | Research only | — | — | 486 | 7 | Medium |
| INSL5 | Research only | — | — | 103 | 0 | Low |
| KPV | Research only | — | — | 45 | 0 | Low |
| KR-12 | Research only | — | — | 42 | 0 | Medium |
| Lactoferricin | Research only | — | — | 242 | 0 | Medium |
| Leuphasyl | Research only | — | — | 11 | 0 | Low |
| Livagen | Research only | — | — | 19 | 0 | Low |
| Magainin | Research only | — | — | 292 | 1 | Low |
| Manserin | Research only | — | — | 3 | 0 | Low |
| Melanin-concentrating hormone | Research only | — | — | 570 | 4 | Medium |
| Melittin | Research only | — | — | 1,486 | 13 | Medium |
| Mod GRF 1-29 | Research only | — | — | 0 | 0 | Low |
| Myristoyl Hexapeptide-16 | Research only | — | — | 0 | 0 | Low |
| Myristoyl Pentapeptide-17 | Research only | — | — | 0 | 0 | Low |
| Myristoyl Tetrapeptide-12 | Research only | — | — | 0 | 0 | Low |
| NA-Selank Amidate | Research only | — | — | 0 | 0 | Low |
| NERP-2 (Neuroendocrine Regulatory Peptide-2) | Research only | — | — | 27 | 2 | Low |
| Nesfatin-1 | Research only | — | — | 407 | 11 | Low |
| Neuromedin B | Research only | — | — | 203 | 2 | Low |
| Neuromedin N (NN) | Research only | — | — | 47 | 0 | Low |
| Neuromedin S | Research only | — | — | 18 | 0 | Low |
| Neuromedin U | Research only | — | — | 176 | 0 | Medium |
| Neuropeptide AF (NPAF) | Research only | — | — | 54 | 2 | Low |
| Neuropeptide B (NPB) | Research only | — | — | 29 | 0 | Low |
| Neuropeptide EI (NEI) | Research only | — | — | 7 | 0 | Low |
| Neuropeptide FF (NPFF) | Research only | — | — | 169 | 0 | Low |
| Neuropeptide W (NPW) | Research only | — | — | 29 | 0 | Low |
| Nocistatin (NST) | Research only | — | — | 27 | 0 | Low |
| Nonapeptide-1 | Research only | — | — | 2 | 1 | Low |
| Nosiheptide | Research only | — | — | 8 | 2 | Low |
| NPAS3 Research Peptide | Research only | — | — | 0 | 0 | Low |
| Octapeptide-2 | Research only | — | — | 0 | 0 | Low |
| Oligopeptide-68 | Research only | — | — | 1 | 1 | Low |
| Ovagen | Research only | — | — | 15 | 2 | Low |
| Pal-GHK | Research only | — | — | 117 | 3 | Medium |
| Palmitoyl Dipeptide-5 Diaminobutyroyl Hydroxythreonine | Research only | — | — | 0 | 0 | Low |
| Palmitoyl Dipeptide-5 Diaminohydroxybutyrate | Research only | — | — | 0 | 0 | Low |
| Palmitoyl Dipeptide-7 | Research only | — | — | 3 | 1 | Low |
| Palmitoyl Hexapeptide-12 | Research only | — | — | 1 | 0 | Low |
| Palmitoyl Hexapeptide-14 | Research only | — | — | 0 | 0 | Low |
| Palmitoyl Pentapeptide-4 | Research only | — | — | 22 | 2 | Medium |
| Palmitoyl Tetrapeptide-10 | Research only | — | — | 0 | 0 | Low |
| Palmitoyl Tetrapeptide-20 | Research only | — | — | 1 | 0 | Low |
| Palmitoyl Tripeptide-28 | Research only | — | — | 0 | 0 | Low |
| Palmitoyl Tripeptide-38 | Research only | — | — | 3 | 0 | Low |
| Palmitoyl Tripeptide-8 | Research only | — | — | 2 | 0 | Low |
| PAMP (Proadrenomedullin N-terminal 20 Peptide) | Research only | — | — | 819 | 7 | Low |
| Pancragen | Research only | — | — | 8 | 0 | Low |
| PE-22-28 | Research only | — | — | 18 | 1 | Low |
| Pentapeptide-3 | Research only | — | — | 4 | 0 | Low |
| Pentapeptide-31 | Research only | — | — | 0 | 0 | Low |
| Pentigetide (IgE Pentapeptide) | Research only | — | — | 103 | 2 | Medium |
| Phoenixin | Research only | — | — | 67 | 0 | Low |
| Pinealon | Research only | — | — | 23 | 0 | Low |
| Prokineticin 1 (EG-VEGF) | Research only | — | — | 180 | 2 | Low |
| Prokineticin 2 | Research only | — | — | 234 | 0 | Low |
| Prolyl-Hydroxyproline | Research only | — | — | 166 | 8 | Low |
| QRFP (26RFa) | Research only | — | — | 61 | 0 | Low |
| Relaxin-3 | Research only | — | — | 152 | 0 | Low |
| RFRP-3 (GnIH) | Research only | — | — | 86 | 3 | Low |
| Secretoneurin (SN) | Research only | — | — | 153 | 1 | Low |
| Serpinin | Research only | — | — | 6 | 0 | Low |
| SHLP2 | Research only | — | — | 16 | 0 | Medium |
| SHLP6 | Research only | — | — | 15 | 0 | Low |
| Spexin | Research only | — | — | 122 | 6 | Low |
| Syn-Ake | Research only | — | — | 2 | 0 | Low |
| TCAP-1 (Teneurin C-terminal Associated Peptide-1) | Research only | — | — | 9 | 0 | Low |
| Teprotide | Research only | — | — | 68 | 0 | Low |
| Tetrapeptide-1 | Research only | — | — | 4 | 0 | Low |
| Tetrapeptide-21 | Research only | — | — | 8 | 2 | Low |
| Tetrapeptide-26 | Research only | — | — | 0 | 0 | Low |
| Tetrapeptide-30 | Research only | — | — | 6 | 2 | Low |
| Thymulin | Research only | — | — | 615 | 10 | Low |
| TLQP-21 | Research only | — | — | 24 | 0 | Low |
| Trifluoroacetyl Tripeptide-2 | Research only | — | — | 0 | 0 | Low |
| Tripeptide-10 Citrulline | Research only | — | — | 3 | 1 | Low |
| Tripeptide-29 | Research only | — | — | 79 | 8 | Low |
| Tripeptide-32 | Research only | — | — | 0 | 0 | Low |
| Tuftsin | Research only | — | — | 232 | 3 | Medium |
| Urocortin 2 | Research only | — | — | 129 | 2 | Low |
| Urocortin 3 | Research only | — | — | 151 | 2 | Low |
| Uroguanylin | Research only | — | — | 206 | 4 | Medium |
| Urotensin II-related peptide | Research only | — | — | 38 | 0 | Low |
| Vessel dilator | Research only | — | — | 118 | 1 | Medium |
| Vesugen | Research only | — | — | 27 | 0 | Low |
| Vilon | Research only | — | — | 229 | 3 | Low |
| WE-14 | Research only | — | — | 21 | 2 | Low |
| Deslorelin | Veterinary | Phase 3 | 4 | 55 | 27 | Medium |
| Emodepside | Veterinary | Phase 3 | 11 | 39 | 23 | Medium |
| Azagly-nafarelin | Veterinary | — | — | 0 | 0 | Low |
| Capromorelin | Veterinary | — | — | 22 | 4 | High |
| Equine Chorionic Gonadotropin | Veterinary | — | — | 716 | 58 | Low |
| Feline Interferon Omega | Veterinary | — | — | 1 | 8 | Low |
| GnRF Analogue–Diphtheria Toxoid Conjugate | Veterinary | — | — | 7 | 20 | Low |
| Gonadorelin (6-D-Phe) | Veterinary | — | — | 0 | 0 | Low |
| Lecirelin | Veterinary | — | — | 0 | 6 | Low |
| Peforelin | Veterinary | — | — | 4 | 3 | Low |
| Pegbovigrastim | Veterinary | — | — | 0 | 0 | Low |
| Porcine FSH | Veterinary | — | — | 73 | 28 | Low |
| Porcine Insulin Zinc Suspension | Veterinary | — | — | 5 | 2 | Medium |
| Sometribove | Veterinary | — | — | 0 | 13 | Low |
| Virginiamycin | Veterinary | — | — | 68 | 21 | Low |
| Bioactive Food Peptides | Supplement | Phase 4 | 1 | 176 | 8 | Medium |
| Carnosine | Supplement | Phase 4 | 21 | 1,386 | 158 | Medium |
| Collagen Peptides | Supplement | Phase 4 | 131 | 16,927 | 1,173 | Medium |
| Melatonin | Supplement | Phase 4 | 403 | 16,290 | 1,205 | Medium |
| Colostrinin | Supplement | — | — | 30 | 2 | Low |
| BNP | Diagnostic | Phase 4 | 139 | 28,708 | 2,612 | High |
| Cholecystokinin | Diagnostic | Phase 4 | 11 | 26,761 | 627 | High |
| Nisin | Food additive | Phase 2 | 2 | 473 | 6 | High |
How to read this tracker
“Status” is the regulatory/development state (read 2026-11-07): FDA approved, approved abroad, in trials, discontinued, withdrawn, or research-only. “Max trial phase” is the highest phase reached for any indication (from ClinicalTrials.gov and the registry), not a claim about any one use. “Registered trials” counts all ClinicalTrials.gov studies at any phase that name the peptide — a measure of how much clinical-trial activity exists, across every indication, not proof of benefit for any one. “Human studies” and “RCTs” are PubMed record counts — how much research exists and of what kind, never proof a peptide works. “Grade” is our editorial reading of the evidence (see how we grade evidence). A discontinued or withdrawn status usually means the evidence, safety or commercial case did not hold — read the entry for the specific reason. Of 662 peptides, 124 are FDA-approved and 326 cite a human trial on their page. See also What Works and the Evidence Explorer.